Mercredi, 8 Juillet 2020
Dernières nouvelles
Principale » AstraZeneca's (LON:AZN) "Buy" Rating Reaffirmed at Kepler Capital Markets

AstraZeneca's (LON:AZN) "Buy" Rating Reaffirmed at Kepler Capital Markets

01 Décembre 2017

Also Investorplace.com published the news titled: "Why AstraZeneca plc (ADR) (AZN), Advanced Micro Devices, Inc". Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company's stock valued at $145,000 after buying an additional 1,769 shares in the last quarter. Dorsey & Whitney Trust CO LLC boosted its stake in Astrazeneca by 0.7% during the second quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company's stock worth $147,000 after acquiring an additional 846 shares in the last quarter. WFG Advisors LP now owns 3,716 shares of the company's stock valued at $127,000 after purchasing an additional 984 shares in the last quarter. Finally, First Interstate Bank grew its stake in Astrazeneca by 10.3% in the 2nd quarter.

Several brokerages have commented on AZN.

Harrison's 2nd annual Christmas Festival & Parade to feature more attractions
Saturday, Dec. 2, 8 to 11 a.m. - Breakfast with Santa, at Essex Elementary School, 12 Story St. $5 per person, $25 per family. Before the boat parade - at 3 p.m. - families can visit Santa's Village on the city pier at the Santa Barbara Harbor.

After a recent technical review, shares of Astrazeneca Plc (AZN.L) have a 200-day moving average of 4865.29. Liberum Capital downgraded shares of Astrazeneca from a "buy" rating to a "hold" rating in a research report on Thursday, September 14th. Cowen reiterated a "hold" rating and issued a $37.00 price objective on shares of Astrazeneca in a research note on Tuesday, October 17th. Citigroup raised shares of Astrazeneca to a "buy" rating in a report on Wednesday, October 18th. BNP Paribas upgraded shares of Astrazeneca from a "neutral" rating to an "outperform" rating in a report on Monday, September 25th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company's stock. The company has an average rating of "Hold" and a consensus target price of $34.20. Investorplace.com's news article titled: "AstraZeneca plc (ADR) (AZN) Shares Soar on Lung Cancer Drug Success" with publication date: May 12, 2017 was also an interesting one. The firm has a market cap of $84,869.16, a P/E ratio of 8.00, a P/E/G ratio of 3.17 and a beta of 0.75. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Thursday, November 9th. The institutional investor held 24,487 shares of the major pharmaceuticals company at the end of 2017Q2, valued at $2.31 million, down from 73,683 at the end of the previous reported quarter. The firm had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $6 billion. Astrazeneca had a net margin of 15.90% and a return on equity of 34.02%. The business's quarterly revenue was up 9.4% compared to the same quarter last year. equities research analysts anticipate that Astrazeneca PLC will post 1.93 earnings per share for the current year. During the same period a year ago, the firm earned $1.32 EPS. If you are accessing this story on another site, it was illegally copied and republished in violation of worldwide copyright law. AstraZeneca plc (ADR) had 39 analyst reports since July 31, 2015 according to SRatingsIntel. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold.